Company Overview and News
IFC, a member of the World Bank Group, is investing $15 million in Senkadagala Finance PLC to help the company expand access to finance for women entrepreneurs across Sri Lanka. This loan is part of the Women Entrepreneurs Opportunity Facility (WEOF), launched by IFC through its Banking on Women (BOW) program, and Goldman Sachs 10,000 Women.
Mar 23, 2018 (LBO) – Sri Lanka’s Senkadagala Finance will get loan of up to US15 million dollars from the International Finance Corporation (IFC), a statement said.
July 24, 2017 (LBO) – Fitch Ratings, a credit ratings agency, has affirmed the long-term issuer default ratings (IDRs) of ten local finance companies, a statement said.
Feb 03, 2017 (LBO) – Sri Lanka’s finance sector player, Senkadagala Finance, is to raise 579 million rupees by way of a rights issue, the company said in a stock exchange filing.
Fitch Ratings has assigned Senkadagala Finance PLC’s (SFC: BBB+(lka)/Stable) issue of senior unsecured redeemable debentures of up to LKR3bn a final National Long-Term Rating of ‘BBB+(lka) ‘.
Fitch Ratings has affirmed the ratings of People’s Leasing & Finance PLC (PLC), Central Finance Company PLC (CF), Melsta Regal Finance Ltd (MRF), HNB Grameen Finance Limited (HGL), LB Finance PLC (LB), Siyapatha Finance PLC (Siyapatha), Senkadagala Finance PLC (Senka), AMW Capital Leasing And Finance PLC (AMCL), Singer Finance PLC (SFL), and Mercantile Investment & Finance PLC (MIF).
Aug 02, 2016 (LBO) – Fitch Ratings has affirmed the ratings of 10 Finance Companies following its periodic review of the large and midsized finance companies in Sri Lanka.
Jun 13, 2016 (LBO) – Sri Lanka’s Senkadagala Finance PLC’s proposed issue of senior unsecured redeemable debentures of up to two billion rupees has been rated ‘BBB+(lka)(EXP)’, Fitch Ratings said in a statement.
Fitch Ratings has assigned Senkadagala Finance PLC’s (SFC: BBB+(lka)/Stable) proposed issue of senior unsecured redeemable debentures of up to LKR2bn an expected National Long-Term rating of ‘BBB+(lka)(EXP)’.
20h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
20h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...